Kruse Bo 4
4 · Y-mAbs Therapeutics, Inc. · Filed May 31, 2024
Insider Transaction Report
Form 4
Kruse Bo
DirectorEVP, CFO, Secy & Treas.
Transactions
- Sale
Common Stock
2024-05-30$12.03/sh−28,629$344,407→ 210,877 total - Sale
Common Stock
2024-05-31$12.07/sh−31,371$378,648→ 210,877 total - Exercise/Conversion
Common Stock
2024-05-30$2.00/sh+28,629$57,258→ 239,506 total - Exercise/Conversion
Common Stock
2024-05-31$2.00/sh+31,371$62,742→ 242,248 total - Exercise/Conversion
Employee Stock Option (right to buy)
2024-05-30−28,629→ 271,371 totalExercise: $2.00Exp: 2025-06-10→ Common Stock (28,629 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2024-05-31−31,371→ 240,000 totalExercise: $2.00Exp: 2025-06-10→ Common Stock (31,371 underlying)
Footnotes (3)
- [F1]This transaction was executed in multiple trades at prices ranging from $11.85 to $12.22, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]This transaction was executed in multiple trades at prices ranging from $11.87 to $12.42, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]All of these stock options are currently vested.